The combination of statin and ezetimibe is safe, effective, and preferable.
No abstract available
References:
Cha J‐J, Kim JH, Hong SJ, Lim S, Joo HJ, Park JH, et al. Safety and efficacy of moderate‐intensity statin with ezetimibe in elderly patients with atherosclerotic cardiovascular disease. J Intern Med. 2024. [Epub ahead of print].
Mammen AL. Statin‐associated autoimmune myopathy. N Engl J Med. 2016;374:664–669.
Cholesterol Treatment Trialists (CTT) collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta‐analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81.
Miettinen TA, Gylling H. Cholesterol synthesis and absorption in coronary patients with lipid triad and isolated high LDL cholesterol in a 4S subgroup. Atherosclerosis. 2003;168:343–9.
Garcia‐Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, et al. The target of ezetimibe is Niemann‐Pick C1‐like 1 (NPC1L1). Proc Natl Acad Sci USA. 2005;102:8132–8137.